{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T16:19:48Z","timestamp":1795277988075,"version":"4.10.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930080"],"award-info":[{"award-number":["81930080"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072926"],"award-info":[{"award-number":["82072926"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972309"],"award-info":[{"award-number":["81972309"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In situ vaccination is a promising strategy to convert the immunosuppressive tumor microenvironment into an immunostimulatory one with limited systemic exposure and side effect. However, sustained clinical benefits require long-term and multidimensional immune activation including innate and adaptive immunity. Here, we develop a probiotic food-grade\n                    <jats:italic>Lactococcus lactis<\/jats:italic>\n                    -based in situ vaccination (FOLactis) expressing a fusion protein of Fms-like tyrosine kinase 3 ligand and co-stimulator OX40 ligand. Intratumoural delivery of FOLactis contributes to local retention and sustained release of therapeutics to thoroughly modulate key components of the antitumour immune response, such as activation of natural killer cells, cytotoxic T lymphocytes, and conventional-type-1-dendritic cells in the tumors and tumor-draining lymph nodes. In addition, intratumoural administration of FOLactis induces a more robust tumor antigen-specific immune response and superior systemic antitumour efficacy in multiple poorly immune cell-infiltrated and anti-PD1-resistant tumors. Specific depletion of different immune cells reveals that CD8\n                    <jats:sup>+<\/jats:sup>\n                    T and natural killer cells are crucial to the in situ vaccine-elicited tumor regression. Our results confirm that FOLactis displays an enhanced antitumour immunity and successfully converts the \u2018cold\u2019 tumors to \u2018hot\u2019 tumors.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-35130-7","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:04:55Z","timestamp":1670036695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy"],"prefix":"10.1038","volume":"13","author":[{"given":"Junmeng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohua","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangcen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanyan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2539-7732","authenticated-orcid":false,"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"35130_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","volume":"18","author":"I Melero","year":"2021","unstructured":"Melero, I., Castanon, E., Alvarez, M., Champiat, S. & Marabelle, A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558\u2013576 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"35130_CR2","doi-asserted-by":"publisher","first-page":"575597","DOI":"10.3389\/fimmu.2020.575597","volume":"11","author":"KG Nguyen","year":"2020","unstructured":"Nguyen, K. G. et al. Localized Interleukin-12 for Cancer Immunotherapy. Front. Immunol. 11, 575597 (2020).","journal-title":"Front. Immunol."},{"key":"35130_CR3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","volume":"25","author":"L Hammerich","year":"2019","unstructured":"Hammerich, L. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 25, 814\u2013824 (2019).","journal-title":"Nat. Med."},{"key":"35130_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/d41573-019-00214-5","volume":"19","author":"K Garber","year":"2020","unstructured":"Garber, K. Immune agonist antibodies face critical test. Nat. Rev. Drug Discov. 19, 3\u20135 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"35130_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.04.043","volume":"61","author":"S Rahimian","year":"2015","unstructured":"Rahimian, S. et al. Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. Biomaterials 61, 33\u201340 (2015).","journal-title":"Biomaterials"},{"key":"35130_CR6","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1021\/acs.biomac.1c01691","volume":"23","author":"BHJ Gowda","year":"2022","unstructured":"Gowda, B. H. J. et al. Stimuli-responsive microneedles as a transdermal drug delivery system: A demand-supply strategy. Biomacromolecules 23, 1519\u20131544 (2022).","journal-title":"Biomacromolecules"},{"key":"35130_CR7","doi-asserted-by":"crossref","unstructured":"Park, C.G. et al. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci. Transl. Med. 10, eaar1916 (2018).","DOI":"10.1126\/scitranslmed.aar1916"},{"key":"35130_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41568-018-0070-z","volume":"18","author":"S Zhou","year":"2018","unstructured":"Zhou, S., Gravekamp, C., Bermudes, D. & Liu, K. Tumour-targeting bacteria engineered to fight cancer. Nat. Rev. Cancer 18, 727\u2013743 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"35130_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coisb.2017.05.009","volume":"5","author":"T Chien","year":"2017","unstructured":"Chien, T., Doshi, A. & Danino, T. Advances in bacterial cancer therapies using synthetic biology. Curr. Opin. Syst. Biol. 5, 1\u20138 (2017).","journal-title":"Curr. Opin. Syst. Biol."},{"key":"35130_CR10","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abc3421","volume":"369","author":"LF Mager","year":"2020","unstructured":"Mager, L. F. et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369, 1481\u20131489 (2020).","journal-title":"Science"},{"key":"35130_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"35130_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"35130_CR13","doi-asserted-by":"crossref","unstructured":"Gurbatri, C.R. et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci. Transl. Med. 12, eaax0876 (2020).","DOI":"10.1126\/scitranslmed.aax0876"},{"key":"35130_CR14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/acscentsci.1c00200","volume":"7","author":"KL Bersch","year":"2021","unstructured":"Bersch, K. L. et al. Bacterial peptidoglycan fragments differentially regulate innate immune signaling. ACS Cent. Sci. 7, 688\u2013696 (2021).","journal-title":"ACS Cent. Sci."},{"key":"35130_CR15","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3389\/fmicb.2018.01821","volume":"9","author":"PA Bron","year":"2018","unstructured":"Bron, P. A. & Kleerebezem, M. Lactic acid bacteria for delivery of endogenous or engineered therapeutic molecules. Front. Microbiol. 9, 1821 (2018).","journal-title":"Front. Microbiol."},{"key":"35130_CR16","doi-asserted-by":"crossref","unstructured":"Garza-Morales, R. et al. Targeting melanoma hypoxia with the food-grade lactic acid bacterium lactococcus lactis. Cancers 12, 438 (2020).","DOI":"10.3390\/cancers12020438"},{"key":"35130_CR17","doi-asserted-by":"crossref","unstructured":"Jin, S. W. et al. Immunomodulatory activity of lactococcus lactis GCWB1176 in cyclophosphamide-induced immunosuppression model. Microorganisms 8, 1175 (2020).","DOI":"10.3390\/microorganisms8081175"},{"key":"35130_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.intimp.2012.10.007","volume":"14","author":"A Kosaka","year":"2012","unstructured":"Kosaka, A. et al. Lactococcus lactis subsp. cremoris FC triggers IFN-\u03b3 production from NK and T cells via IL-12 and IL-18. Int. Immunopharmacol. 14, 729\u2013733 (2012).","journal-title":"Int. Immunopharmacol."},{"key":"35130_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ebiom.2016.06.046","volume":"9","author":"CJ Breitbach","year":"2016","unstructured":"Breitbach, C. J., Lichty, B. D. & Bell, J. C. Oncolytic viruses: Therapeutics with an identity crisis. EBioMedicine 9, 31\u201336 (2016).","journal-title":"EBioMedicine"},{"key":"35130_CR20","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","volume":"170","author":"AK Nowak","year":"2003","unstructured":"Nowak, A. K. et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. 170, 4905\u20134913 (2003).","journal-title":"J. Immunol."},{"key":"35130_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/sj.cdd.4402255","volume":"15","author":"RG van der Most","year":"2008","unstructured":"van der Most, R. G., Currie, A. J., Robinson, B. W. & Lake, R. A. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ. 15, 13\u201320 (2008).","journal-title":"Cell Death Differ."},{"key":"35130_CR22","doi-asserted-by":"crossref","unstructured":"Garbacz, K. Anticancer activity of lactic acid bacteria. Semin. Cancer Biol. 86, 356\u2013366 (2022).","DOI":"10.1016\/j.semcancer.2021.12.013"},{"key":"35130_CR23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","volume":"21","author":"J Lai","year":"2020","unstructured":"Lai, J. et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat. Immunol. 21, 914\u2013926 (2020).","journal-title":"Nat. Immunol."},{"key":"35130_CR24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022\u20131037.e1014 (2018).","journal-title":"Cell"},{"key":"35130_CR25","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1002\/ijc.28937","volume":"135","author":"KS Voo","year":"2014","unstructured":"Voo, K. S. et al. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int. J. Cancer 135, 2834\u20132846 (2014).","journal-title":"Int. J. Cancer"},{"key":"35130_CR26","doi-asserted-by":"crossref","unstructured":"Sagiv-Barfi, I. et al. Eradication of spontaneous malignancy by local immunotherapy. Sci. Transl. Med. 10, eaan4488 (2018).","DOI":"10.1126\/scitranslmed.aan4488"},{"key":"35130_CR27","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1111\/cas.15145","volume":"112","author":"Y Chu","year":"2021","unstructured":"Chu, Y. et al. Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination. Cancer Sci. 112, 4490\u20134500 (2021).","journal-title":"Cancer Sci."},{"key":"35130_CR28","doi-asserted-by":"crossref","unstructured":"Wang, C. & Steinmetz, N.F. A combination of Cowpea Mosaic virus and immune checkpoint therapy synergistically improves therapeutic efficacy in three tumor models. Adv. Funct. Mater. 30, 2002299 (2020).","DOI":"10.1002\/adfm.202002299"},{"key":"35130_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","volume":"11","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo, J. A. et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J. Hematol. Oncol. 11, 39 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"35130_CR30","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1021\/bm500296n","volume":"15","author":"D Bacinello","year":"2014","unstructured":"Bacinello, D., Garanger, E., Taton, D., Tam, K. C. & Lecommandoux, S. Enzyme-degradable self-assembled nanostructures from polymer\u2013peptide hybrids. Biomacromolecules 15, 1882\u20131888 (2014).","journal-title":"Biomacromolecules"},{"key":"35130_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado, R. L., Balan, S. & Bhardwaj, N. Dendritic cell-based immunotherapy. Cell Res. 27, 74\u201395 (2017).","journal-title":"Cell Res."},{"key":"35130_CR32","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1111\/cmi.12170","volume":"15","author":"ET Berends","year":"2013","unstructured":"Berends, E. T. et al. Distinct localization of the complement C5b-9 complex on Gram-positive bacteria. Cell Microbiol. 15, 1955\u20131968 (2013).","journal-title":"Cell Microbiol."},{"key":"35130_CR33","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1177\/0022034515611074","volume":"94","author":"C Jeanneau","year":"2015","unstructured":"Jeanneau, C. et al. Can pulp fibroblasts kill cariogenic bacteria? Role of complement activation. J. Dent. Res. 94, 1765\u20131772 (2015).","journal-title":"J. Dent. Res."},{"key":"35130_CR34","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.immuni.2016.02.026","volume":"44","author":"S Gordon","year":"2016","unstructured":"Gordon, S. Phagocytosis: an immunobiologic process. Immunity 44, 463\u2013475 (2016).","journal-title":"Immunity"},{"key":"35130_CR35","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nri3244","volume":"12","author":"DM Underhill","year":"2012","unstructured":"Underhill, D. M. & Goodridge, H. S. Information processing during phagocytosis. Nat. Rev. Immunol. 12, 492\u2013502 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"35130_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1600-065X.2007.00552.x","volume":"219","author":"A Savina","year":"2007","unstructured":"Savina, A. & Amigorena, S. Phagocytosis and antigen presentation in dendritic cells. Immunol. Rev. 219, 143\u2013156 (2007).","journal-title":"Immunol. Rev."},{"key":"35130_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/cmi.2010.22","volume":"7","author":"S Leung","year":"2010","unstructured":"Leung, S. et al. The cytokine milieu in the interplay of pathogenic Th1\/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol. Immunol. 7, 182\u2013189 (2010).","journal-title":"Cell Mol. Immunol."},{"key":"35130_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cell.2004.07.002","volume":"118","author":"S Rakoff-Nahoum","year":"2004","unstructured":"Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118, 229\u2013241 (2004).","journal-title":"Cell"},{"key":"35130_CR39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487\u2013502.e415 (2017).","journal-title":"Cell"},{"key":"35130_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ni889","volume":"4","author":"EJ Wherry","year":"2003","unstructured":"Wherry, E. J. et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4, 225\u2013234 (2003).","journal-title":"Nat. Immunol."},{"key":"35130_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/01.cji.0000436722.46675.4a","volume":"36","author":"MG Lechner","year":"2013","unstructured":"Lechner, M. G. et al. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J. Immunother. 36, 477\u2013489 (2013).","journal-title":"J. Immunother."},{"key":"35130_CR42","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.cgh.2006.03.028","volume":"4","author":"H Braat","year":"2006","unstructured":"Braat, H. et al. A phase I trial with transgenic bacteria expressing interleukin\u221210 in Crohn\u2019s disease. Clin. Gastroenterol. Hepatol. 4, 754\u2013759 (2006).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"35130_CR43","doi-asserted-by":"publisher","first-page":"27299","DOI":"10.1074\/jbc.270.45.27299","volume":"270","author":"OP Kuipers","year":"1995","unstructured":"Kuipers, O. P., Beerthuyzen, M. M., de Ruyter, P. G., Luesink, E. J. & de Vos, W. M. Autoregulation of nisin biosynthesis in Lactococcus lactis by signal transduction. J. Biol. Chem. 270, 27299\u201327304 (1995).","journal-title":"J. Biol. Chem."},{"key":"35130_CR44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31, 311\u2013325 (2017).","journal-title":"Cancer Cell"},{"key":"35130_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2017.05.011","volume":"114","author":"L Milling","year":"2017","unstructured":"Milling, L., Zhang, Y. & Irvine, D. J. Delivering safer immunotherapies for cancer. Adv. Drug Deliv. Rev. 114, 79\u2013101 (2017).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"35130_CR46","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts, E. W. et al. Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30, 324\u2013336 (2016).","journal-title":"Cancer Cell"},{"key":"35130_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature 523, 231\u2013235 (2015).","journal-title":"Nature"},{"key":"35130_CR48","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.4049\/jimmunol.2000347","volume":"205","author":"T Oba","year":"2020","unstructured":"Oba, T. et al. A critical role of CD40 and CD70 signaling in conventional type 1 dendritic cells in expansion and antitumor efficacy of adoptively transferred tumor-specific T cells. J. Immunol. 205, 1867\u20131877 (2020).","journal-title":"J. Immunol."},{"key":"35130_CR49","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","volume":"54","author":"JM Schenkel","year":"2021","unstructured":"Schenkel, J. M. et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF\u22121(+) CD8(+) T cells in tumor-draining lymph nodes. Immunity 54, 2338\u20132353.e2336 (2021).","journal-title":"Immunity"},{"key":"35130_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19192-z","volume":"11","author":"T Oba","year":"2020","unstructured":"Oba, T. et al. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nat. Commun. 11, 5415 (2020).","journal-title":"Nat. Commun."},{"key":"35130_CR51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2015.08.021","volume":"52","author":"S Aspeslagh","year":"2016","unstructured":"Aspeslagh, S. et al. Rationale for anti-OX40 cancer immunotherapy. Eur. J. Cancer 52, 50\u201366 (2016).","journal-title":"Eur. J. Cancer"},{"key":"35130_CR52","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/icb.2014.26","volume":"92","author":"Y Bulliard","year":"2014","unstructured":"Bulliard, Y. et al. OX40 engagement depletes intratumoral Tregs via activating Fc\u03b3Rs, leading to antitumor efficacy. Immunol. Cell Biol. 92, 475\u2013480 (2014).","journal-title":"Immunol. Cell Biol."},{"key":"35130_CR53","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","volume":"223","author":"MB Lutz","year":"1999","unstructured":"Lutz, M. B. et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223, 77\u201392 (1999).","journal-title":"J. Immunol. Methods"},{"key":"35130_CR54","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1039\/D0BM01731K","volume":"9","author":"X Pei","year":"2021","unstructured":"Pei, X. et al. 4T1 cell membrane fragment reunited PAMAM polymer units disguised as tumor cell clusters for tumor homotypic targeting and anti-metastasis treatment. Biomater. Sci. 9, 1325\u20131333 (2021).","journal-title":"Biomater. Sci."},{"key":"35130_CR55","doi-asserted-by":"publisher","first-page":"10785","DOI":"10.18632\/oncotarget.13911","volume":"8","author":"LB Pathangey","year":"2017","unstructured":"Pathangey, L. B. et al. Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2\/neu and other tumor-associated antigens. Oncotarget 8, 10785\u201310808 (2017).","journal-title":"Oncotarget"},{"key":"35130_CR56","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41551-021-00831-9","volume":"6","author":"Y Agarwal","year":"2022","unstructured":"Agarwal, Y. et al. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nat. Biomed. Eng. 6, 129\u2013143 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"35130_CR57","doi-asserted-by":"crossref","unstructured":"Chen, L. et al. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci. Transl. Med. 13, eabc2816 (2021).","DOI":"10.1126\/scitranslmed.abc2816"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35130-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35130-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35130-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T04:03:41Z","timestamp":1670040221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35130-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["35130"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-35130-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]},"assertion":[{"value":"6 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7466"}}